Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article

Review Article | Open Access

Volume 2020 |Article ID 8035301 | https://doi.org/10.1155/2020/8035301

Scott A. Johnson, Damian Rodriguez, Kathryn Allred, "A Systematic Review of Essential Oils and the Endocannabinoid System: A Connection Worthy of Further Exploration", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 8035301, 13 pages, 2020. https://doi.org/10.1155/2020/8035301

A Systematic Review of Essential Oils and the Endocannabinoid System: A Connection Worthy of Further Exploration

Academic Editor: Tadaaki Satou
Received10 Jan 2020
Revised21 Apr 2020
Accepted04 May 2020
Published16 May 2020


Aromatic compounds have a long history of use as medicines in most recorded cultures. An increasing interest in these therapeutic volatile molecules in both scientific and lay communities has led to the advancement of essential oils as phytomedicines. Recent discoveries suggest essential oils augment the endocannabinoid system in a positive manner to mitigate various pathologies. However, the exact mechanisms whereby essential oils influence endocannabinoid system activity are not fully known, these studies provide a glimpse into their involvement and warrant further evaluation. Additional study of the interaction between essential oils and the endocannabinoid system may lead to promising phytomedicines for the treatment of diseases and conditions involving dysregulation or activation of the endocannabinoid system.

1. Introduction

Aromatherapy is one of the most widely used integrative therapies in the world, with a rich tradition dating back centuries. Volatile aromatic compounds distilled or expressed from plants—leaves, flowers, seeds, bark, resins, and more—called essential oils are used medicinally for a variety of ailments. Volatile extracts produced by solvent extraction are not considered true essential oils. One exception may be volatile concentrates extracted with carbon dioxide (typically in a supercritical state), which can produce essential oils very similar to traditionally distilled or expressed essential oils without adding any solvent to the end product. Supercritical carbon dioxide extraction of aromatic molecules can be either “select” or “total.” Select extracts frequently mimic traditionally distilled essential oils in chemical composition, whereas total extracts contain large amounts of nonvolatile constituents in them and are dissimilar to their traditionally obtained counterparts. These extracts are highly purified and concentrated with aromas authentic to the original plant materials. Despite the similarity between supercritical select extracts and traditionally distilled essential oils, they are not universally accepted as essential oils and many prefer to distinguish them as plant extracts rather than essential oils.

Essential oils are complex mixtures of volatile aromatic compounds mainly composed of terpenes biosynthesized by the mevalonate pathway [1]. Furthermore, they contain phenolic compounds derived from the shikimate pathway. These therapeutic compounds can be absorbed through the olfactory system (inhalation), through the skin (topically), or by oral administration [2]. Less commonly, they are administered transmucosally via the rectum or vagina. Plant essential oils contain lipophilic volatiles that freely cross cellular membranes. Once absorbed, their chemical diversity, low molecular weight, and structure allow them to produce a wide spectrum of activity through multiple pathways, mechanisms, and pharmacological targets.

A large body of evidence describes the effects of odors on the human brain and emotions. Essential oil molecules are uniquely qualified to influence mood, alertness, stress, anxiety, and task performance because of their direct connection to areas of the brain involved in emotions and cognition, especially the limbic system [3]. Studies evaluating the effects of essential oils on human physiology and specific disease states are also growing, but much of this to date has been performed in vitro or animal research. Hundreds of clinical trials have also investigated essential oils, with the majority occurring in the last decade. Nevertheless, multiple promising properties have been confirmed—anxiolytic, antidepressant, anti-inflammatory, analgesic, hormonogenic, antidiabetic, antitumoral, immunomodulatory, and more—that await confirmation in randomized, controlled, and blinded human trials [3].

A growing interest in the endocannabinoid system (ECS) and its effects on human health and physiology has emerged as a consequence of relaxing legislative restriction on Cannabis spp. plant extracts and their active constituents, such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). The ECS is a system of enzymes (that control the production and degradation of endogenous cannabinoids), cannabinoid receptors (CB1R and CB2R), and molecules that interact with these receptors. Cannabinoid receptors type 1 (CB1R) are predominantly expressed in the central nervous system (CNS), making them a potential target for neuropsychological disorders and neurodegenerative diseases [46]. The primary drawback to molecules that bind to CB1R is their psychoactive potential, which may limit therapeutic use [7]. Indeed, activation of CB1R may, in some cases, precipitate episodes of psychosis and panic [7]. On the other hand, inhibiting CB1R could produce depressive or anxiety-related behaviors. All of this needs to be taken into account when treating individuals through exploitation of the endocannabinoid system.

On the contrary, cannabinoid receptor type 2 (CB2R) are widely expressed in the immune system and periphery. CB2R is a promising target for inflammatory conditions, neuropathic pain, and immune modulation [8, 9]. Activation or upregulation of CB2R induces receptor conformational rearrangements that can affect myriad signaling pathways, which is vital for therapeutic activity [8]. They have been the subject of considerable attention primarily due to their promising therapeutic potential while avoiding undesirable psychotropic effects associated with CB1R agonists.

Cannabinoids can modulate immune cell function, activity, and secretion of cytokines [10, 11]. Compounds that activate CB2R are of particular interest for their immunomodulatory activity because these receptors are predominantly expressed in the immune system. CB2R is expressed in human leukocytes, B cells, basophils, dendritic cells, eosinophils, mast cells, macrophages, microglia, monocytes, natural killer cells, neutrophils, platelets, and T cells, highlighting its potential in immune modulation [9]. The complexity of the immune system means it has ample opportunity to fall out of balance and be under- or overactive. The role of the ECS in immune regulation—overall function, tone, and activity—is very important. Inflammation plays a crucial role in the immune system’s defensive response to harmful stimuli, such as pathogens and injury. Autoimmune diseases frequently involve a chronic hyperinflammatory response. Endogenous cannabinoids can modulate inflammation both through direct cannabinoid receptor binding and other mechanisms [12]. Emerging evidence shows that phytocannabinoids also exert regulatory control over immune and inflammatory responses [1316]. It is likely that the subtle but significant role of the ECS in immune regulation can be exploited in the management of human disease.

Both CB1R and CB2R are distributed in various organs and tissues throughout the body, affecting every major organ of the body and whose expression changes in disease states [17]. It is well known that these receptors and the molecules that interact with them have a significant signaling and regulatory effect on cells, tissues, organs, and organ systems [18]. Indeed, the ECS is vital for human survival and plays a critical role in maintaining homeostasis so much so that some consider it the “master regulator” of the human body [19].

Given the interest in both EOs and the ECS, a systematic review was conducted to determine current evidence for use of EOs as therapeutic agents for conditions involving dysregulation of the ECS.

2. Methods

2.1. Systematic Review

The present review employed a systematic search of the National Institute of Health PubMed database for all articles containing the keywords “essential oil,” “aromatherapy,” and “beta-caryophyllene” together with either of three key words or phrases “endocannabinoid system,” “endocannabinoid,” or “cannabinoid.” Only primary research articles published in the English language between 1960 and 2020 (up to January 10, 2020) with relevant information on EOs that modulate endocannabinoid system activity were included in the review. Publications documenting the activity of methanolic extracts or aqueous extracts were excluded.

Of the 20 research articles identified in the initial search, three were excluded as they primarily mentioned beta-caryophyllene as a cannabinoid and are not relevant to EO modulation of the ECS. A total of 17 articles meeting the inclusion criteria were systematically reviewed and the research documented for ECS modulation.

Research directly related to the subject matter was in vitro and animal in vivo. No clinical trials have been conducted on EOs and ECS modulation.

3. Results

3.1. Beta-Caryophyllene

Widely distributed in essential oils, black pepper (Piper nigrum), melissa (Melissa officinalis), guava leaf (Psidium guajava), hemp (Cannabis sativa), clove (Eugenia caryophyllata), and ylang ylang (Cananga odorata), but most abundantly found in copaiba (Copaifera spp.; up to 87.3%) [20], beta-caryophyllene (BCP) is a sesquiterpene alkene and atypical dietary cannabinoid [2125]. In nature, BCP is frequently found together with small quantities of its isomers, isocaryophyllene, and alpha-humulene or in mixture with its oxidation product caryophyllene oxide. BCP is well researched and shares similar properties (e.g., analgesic and anti-inflammatory) to other cannabinoids, which allow it to initiate similar physiological responses in the ECS. It is a full selective agonist of CB2R, allowing for a therapeutic action without the psychoactive effects of cannabinoids that bind to CB1R [26, 27]. BCP is considered nontoxic with a wide safety margin [28]. It is considered a functional nonpsychoactive, polypharmacological dietary cannabinoid and anti-inflammatory agent with a demonstrated activity on a number of receptor targets in the human body [29]. Essential oils that contain BCP have a direct action on the ECS, as BCP binds to CB2R.

BCP (see its chemical structure in Figure 1) is an attractive compound for chronic pain (both inflammatory and neurogenic) due to its direct action on CB2R without creating a tolerance, as demonstrated in an animal model of neuropathic pain [30]. Remarkably, the researchers concluded that the effect of BCP became stronger during the treatment period. This is significant considering drug tolerance after prolonged use is observed with other analgesic therapies and may require increased dosage, which may accelerate tolerance and further reduce the effects of a therapeutic substance. BCP exerts potent anti-inflammatory effects when taken orally, which may be explained by its ability to simultaneously inhibit pathways (toll-like receptor complex CD14/TLR4/MD2) that increase the production of proinflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-), reduce immune-related inflammation, and synergize the µ-opioid receptor pathways [28, 31]. Preclinical models demonstrate that BCP can reduce inflammation in a variety of bacterial-caused, eosinophil-related, and neuropathic inflammatory conditions [32]. It can also enhance the effects of other pain medications like morphine, making it a promising candidate to reduce effective drug dose and therefore potential drug dependence and tolerance [33]. In this way, it modulates pain signaling pathways in a manner that may enhance, and not compete with, the benefits of other pain-or inflammation-relieving substances.

BCP modulates multiple pathways involved in cancer pathogenesis including MAPK, PI3K/AKT/mTOR/S6K1, and STAT3 (Figure 2), activates cytotoxic pathways against tumors, potentiates pathways that hinder metastasis, reduces the expression of oncogenes and proteins, and simultaneously increases genes and proteins that destroy cancer cells [3437]. Laboratory studies suggest BCP has promise against kidney, lung, colorectal, liver, oral, melanoma, leukemia, lymphoma, and neuroblastoma cancers and possesses chemopreventive properties [32, 38, 39].

BCP shows promise for treating depression and stress related mental illnesses due to its direct binding to CB2R, which modulates ECS activity (Table 1) [40]. The ECS controls cognitive and emotional responses to stressors through CBR interactions. In addition, preclinical research suggests BCP is a neuroprotective, antidiabetic, antioxidant, and anticonvulsive agent, reduces neuroinflammation, improves lipid profiles, alleviates endometriosis, exhibits promise for interstitial cystitis, is helpful for substance abuse disorders, and protects against nonalcoholic fatty liver disease [13, 32, 4153].

Essential oilECS activity

Copaiba, guava leaf, black pepper, hemp, melissa, clove, ylang ylangCB2R agonist

LavenderInhibits FAAH and MAGL enzymes

CedarwoodActivates central CB1R and CB2R

MasticIncreases cannabinoid congeners palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)
Chir pineCB2R agonist

WormwoodWeakly affects ECS at higher concentrations

Essential oils that contain moderate to high levels of the active compound beta-caryophyllene.
3.2. Lavender (Lavandula angustifolia) Essential Oil

Lavender is one of the most popular and widely studied essential oils. It is primarily composed of linalool (25%–45%) and linalyl acetate (25%–46%) but also contains moderate levels of beta-caryophyllene, (Z)-beta-ocimene, (E)-beta-ocimene, and lavandulyl acetate [5456]. It is frequently used in aromatherapy for the skin, anxiety, stress, pain, and to improve sleep [57].

Neuropathic pain is one of the most difficult conditions to treat, and more effective treatment options are urgently needed. A 2019 study investigated the benefits of oral administration of lavender (36.0% linalyl acetate, 35.3% linalool, 3.4% beta-caryophyllene) for neuropathic pain in mice [58]. Mice with spared nerve injury were administered 100 mg/kg body weight as an acute dose, which alleviated SNI-induced mechanical allodynia with efficacy comparable to the reference drug pregabalin.

Further investigation of the mechanism of action by the study authors found that lavender essential oil markedly decreased the phosphorylation of ERK1, ERK2, and JNK1 and decreased the levels of iNOS in the spinal cord. Additionally, lavender essential oil inhibited the endocannabinoid degradation enzymes FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase), particularly FAAH (Table 1). FAAH and MAGL can synthesize or degrade endocannabinoids depending on body needs. FAAH inhibition is beneficial in CNS and pain disorders due to conservation of endocannabinoids and enhancement of endocannabinoid signaling [59, 60]. Elevation of endocannabinoids causes marked antinociception in neuropathic pain models [61, 62]. The signaling function of the endogenous cannabinoid N-arachidonoylethanolamide (AEA; also known as anandamide) is terminated by enzyme hydrolysis principally involving FAAH, which directly affects specific brain regions related to emotionality, behavior planning, and motivation (hippocampus, striatum, and frontal cortex) [63, 64]. The blockade of FAAH and MAGL enzymatic activity is considered a therapeutic target for neuropathic pain relief and may also alleviate inflammatory bowel diseases, anxiety, cancer metastasis, and Alzheimer’s diseases (Figure 3) [65, 66]. A primary advantage of FAAH inhibitors is their modulation of the ECS without psychotropic effects. This research highlights the need to investigate other essential oils with demonstrated analgesic and antinociceptive activity and whether this activity is related to endocannabinoid enzyme blockade.

3.3. Atlas Cedarwood (Cedrus atlantica) Essential Oil

Atlas cedarwood is typically very rich in sesquiterpenes (primarily himachalenes) and frequently used in aromatherapy for nervous disorders like anxiety and stress. Research shows that Atlas cedarwood possesses analgesic, anti-inflammatory,anti-leukemic, and insecticidal properties [6770].

Italian researchers who previously discovered the analgesic activity of cedarwood via inhalation in a model of postoperative pain designed an additional study to identify its mechanism of action [71]. Male Swiss mice were subject to plantar incision. CB1R and CB2R antagonists (AM281 and AM630) were administered in different sites (intraperitoneal, intraplantar, and intrathecal), and the FAAH and MAGL endocannabinoid degradation inhibitors (URB937 and JZL184) were employed to determine ECS system involvement.

Cedarwood essential oil (46.6% beta-himachalene, 16.6% alpha-himachalene, and 10.4% gamma-himachalene) was inhaled by positioning 200 μL of the oil at the bottom of the cage in a Petri dish. Incised mice were then introduced into the cage for 30 minutes of inhalation. CBR antagonists were administered twenty minutes prior to exposure to the oil. Animals were also pretreated with FAAH and MAGL inhibitors 1.5 hours prior to cedarwood inhalation to test if inhibition of these enzymes was involved in cedarwood’s antihyperalgesic effects.

Inhalation of cedarwood produced a significant antihyperalgesic effect. Pretreatment with CB1R and CB2R antagonists prevented the antihyperalgesic activity of cedarwood oil inhalation. The observed effects show that the antihyperalgesic effects of cedarwood oil inhalation are mediated through the activation of central CB1R and CB2R (Table 1 and Figure 4) but not peripheral receptors. Inhibition of FAAH and MAGL prolonged the antihyperalgesic effects of cedarwood inhalation with activity occurring as early as 30 minutes and remaining for up to six hours after exposure. This study demonstrates that cedarwood essential oil reduces postoperative hyperalgesia through activation of descending pain modulation pathways via activation of CNS pathways (opioidergic, serotonergic, noradrenergic, and dopaminergic) and activation of central CBR.

The findings are interesting since no known phytocannabinoid or CBR ligand is present in cedarwood essential oil. BCP may be present in trace amounts occasionally, but it is not always present and was not reported in this study as a constituent of the oil. This suggests that Cedrus atlantica essential oil may stimulate the release of endocannabinoids or inhibit their degradation by enzymes to enhance regulation of homeostasis by the ECS, and further research is warranted to investigate if other essential oils have similar effects.

3.4. Mastic (Pistacia lentiscus) Essential Oil

Mastic leaf essential oil is obtained via supercritical carbon dioxide extraction or traditional steam distillation from the gum resin, leaves, or fruits. Perhaps due to its low yield, it is less commonly used in aromatherapy. However, mastic oil is used in aromatherapy and both mastic extract and the essential oil are used for their antihypertensive, anti-inflammatory, analgesic, antiseptic, and respiratory supportive properties, as well as in the treatment of gastric disorders [7274]. Its composition varies widely according to the published research [2].

Mastic leaf essential oil (a carbon dioxide select extract) consisting of 19.9% germacrene D, 8.7% gamma-cadinene, 6.6% beta-caryophyllene, 6.3% alpha-pinene, 5.8% sabinene, 4.2% delta-cadinene, 3.9% myrcene, and 3.7% beta-phellandrene was evaluated for protection against brain tissue damage caused by an ischemia/reperfusion injury [75].

Cerebral ischemia is caused by occlusion of internal carotid artery, which interrupts brain circulation and prevents cerebral tissue from maintaining basal metabolism. Following this occlusion, a cascade of interconnected pathophysiological events occurs that alters the structure and functional organization of the brain [76, 77]. Reperfusion of neural ischemic tissue after occlusion leads to oxidative stress that can eventually cause neuronal death [78]. Furthermore, altered endocannabinoid levels have been observed in people with acute ischemic stroke, likely as an adaptive mechanism due to neuronal death [79, 80]. Moreover, increased expression of CB2R is noted in the brainstem, microglia, and astrocytes after CNS insults, such as neuroinflammation [8183]. Given its potent anti-inflammatory activities, CB2R activation has been proven to reduce postischemic inflammation [84]. In addition, CB2R have the potential to restrain the inflammatory process that contributes to the decline of neural function in neurodegenerative disease [85].

In the aforementioned study evaluating mastic essential oil against brain tissue damage, male Wistar rats were subject to transient bilateral common carotid artery occlusion followed by reperfusion. Gavage administration of 200 mg of mastic leaf essential oil (containing about 60 mg/kg bodyweight of BCP) in 0.45 mL sunflower oil occurred six hours prior to ischemia. Analysis of the frontal cortex and the remaining posterior cortex of rats showed that brain DHA levels were preserved in rats pretreated with mastic essential oil. An increase in the DHA-to-EPA ratio and significantly increased levels of cannabinoid congeners palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) were also observed (Table 1 and Figure 5). An increased DHA-to-EPA ratio may indicate an increased metabolism of omega-3 fatty acids to supply damaged brain tissue with newly produced DHA or prompt metabolism of EPA to DHA due to augmented EPA entry into the brain. Cyclooxygenase-2 (COX-2) levels were significantly decreased in the frontal cortex in rats pretreated with mastic essential oil compared with control, suggesting less neuroinflammation. No change was observed in levels of two endocannabinoids, AEA, or 2-arachidonoyl-monoacylglycerol (2-AG).

The present study demonstrates that a single dose of mastic essential oil is sufficient to mitigate stroke damage by modifying ECS congener profiles. Altogether, the findings suggest a preservation of brain structure and reduced neuroinflammation and neuronal loss.

A possible explanation of the observed ECS effects is the presence of moderate amounts of BCP. BCP prevents activation of the ECS after ischemia reperfusion injury, spares DHA levels, and prevents increases in COX-2 and peroxisome-proliferator activated receptor-alpha (PPAR-alpha) protein levels [86]. The same research showed that BCP significantly reduces AEA levels (−56%; post hoc adjusted ) after ischemia reperfusion injury. The evidence suggests BCP induces positive modulation of the ECS and lipid peroxidation to control damage caused by hypoperfusion/reperfusion-induced oxidative stress injury. Nevertheless, synergistic effects by other aromatic volatile compounds, some of which have demonstrated antioxidant and anti-inflammatory activity, cannot be ruled out.

3.5. Chir Pine (Pinus roxburghii) Essential Oil

Chir pine is an evergreen, coniferous tree native to the Himalayas. Essential oil can be extracted from various parts of the tree, including the needles, bark, wood, and cones. Depending on the plant parts used and other factors, chir pine essential oil produces essential oil with a variety of compositions and major aromatic compounds. It does produce a type rich in beta-caryophyllene from the needles, cones, wood, and bark. Interestingly, researchers found that a chemotype devoid of beta-caryophyllene but rich in the sesquiterpene longifolene (33.1%) and also palmitic acid (9.3%) and longicamphenylone (7.9%) binds to CB2R [87].

Many of the aromatic compounds (listed in descending binding affinity: palmitic acid, 1-octadecanol, myristic acid, dodecanoic acid, 7 (11)-selin-4-alpha-ol, caryophyllene oxide, humulene-1,6-dien-3-ol, longicyclene, longifolene, longicamphenylone, myrtenal, alpha-pinene, terpinolene, and delta-3-carene) within the oil also readily bound to glucocorticoid receptors. The endocannabinoid system plays a complex and critical role in the regulation of glucocorticoid-mediated hypothalamic-pituitary-adrenal (HPA) axis negative feedback, which is the major neuroendocrine axis regulating homeostasis in mammals. Under basal conditions, glucocorticoids are released rhythmically to maintain homeostasis with both a circadian and ultradian pattern. The robust rhythm in circulating glucocorticoid levels is vital to the normal function of glucocorticoid target organs and the HPA axis response to stress. The disruption of these rhythms is associated with disease in humans [88]. Glucocorticoid hormones are rapidly synthesized from the adrenal gland in response to stress. Consequently, a rapid loss of AEA in the amygdala occurs, possibly through rapid induction of FAAH-mediated hydrolysis [89]. The magnitude by which AEA is degraded negatively correlates with the extent of HPA axis activation. Greater AEA loss elicits correspondingly greater increases in corticosterone secretion [89]. As such, proper ECS tone under steady-state conditions acts to suppress the excitatory activity induced by glutamate signaling in the basolateral nucleus of the amygdala. This data is evidence that the ECS plays a crucial role in HPA response. Another correlation between glucocorticoids and the ECS is the ability of glucocorticoids to rapidly induce 2-AG synthesis in the hypothalamus [90]. At the functional level, interest in glucocorticoid and ECS interactions is growing.

Chir oil was administered (100 mg/kg body weight, p.o.) in mice, producing a significant anti-inflammatory activity and improved antioxidant activity (Figure 6), specifically elevation of superoxide dismutase and catalase activity. Superoxide dismutase and catalase are enzymes that protect cells from free radical assault by reactive oxygen species, specifically hydrogen peroxide and superoxide anion. Emerging evidence suggests that crosstalk between the ECS and reactive oxygen species signaling systems acts to modulate ECS functionality as well as redox homeostasis in different cell types [91]. The ECS is involved in regulation of reactive oxygen species generating and scavenging mechanisms and redox can modulate ECS function emphasizing an interplay between these two prominent signaling systems. In addition to binding to CB2R (Table 1), the oil activated , , and opioid receptors, suggesting that the oil may be beneficial for painful inflammatory conditions. It is possible that longifolene or other terpenoids present in the oil possess binding affinity for CB2R, or a biotransformation is occurring after ingestion to a compound with CB2R binding affinity. Biotransformation of longifolene to alcohols in mammals has been reported [92].

3.6. Wormwood (Artemisia absinthium) Essential Oil

Wormwood essential oil is not commonly used in aromatherapy and not widely available commercially. Preclinical research has identified that wormwood essential oil has pharmacological activities such as antioxidant, antimicrobial, and antiparasitic [9395]. Absinthe is a potent alcoholic drink distilled from green anise, fennel, wormwood oil, and other herbs that has potential for both harm and abuse [96, 97]. The drink is believed to produce hallucinations with intense euphoria. Thujone is the active compound in wormwood essential oil, but also found in sage and tansy essential oils [98]. Speculating that thujone may interact with CB1R and result in absinthe’s observed intoxicating effects, researchers investigated the effects of thujone on the ECS.

Using radioligand receptor binding assays and membrane preparation from rat brains containing CB1R and human tonsils with CB2R, the researchers demonstrated that thujone displaced the synthetic cannabinoid [3H]CP 55,940—a full agonist of CB1R and CB2R—only at higher concentrations than the synthetic (Figure 7) [99]. It had a very low binding affinity for CBR and failed to stimulate G-proteins even at 0.1 mM. In addition, rats administered thujone exhibited dissimilar behavior compared with rats administered levonantradol (a potent cannabinoid agonist). The data suggest that wormwood essential oil, rich in thujone, only weakly affects ECS function in higher concentrations (Table 1).

4. Discussion

Essential oils are complex mixtures of volatile organic compounds, which generally contain dozens to hundreds of low molecular weight compounds. In general, monoterpenes and sesquiterpenes are the predominant compounds of essential oils. Terpenes are a potential source of lipid modulators of the endogenous lipid systems, including the ECS, with the ability to stimulate cannabinergic signaling [28, 100, 101]. Some compounds can dominate the composition of the essential oil (such as methyl salicylate, which makes up more than 95% of genuine wintergreen oil), while others may be present in only fractions (such as incensole acetate in frankincense). Sometimes the main compound is responsible for the biological effects of the oil, but this is not always the case, and frequently greater activity is observed with the whole oil rather than isolated major compounds [2]. Among plant products, essential oils deserve particular attention for clinical use because of their use in numerous healing systems throughout the history.

Previous research has shown that essential oils with no known phytocannabinoids or CBR ligands in their composition may have ECS modulating properties, so as to attribute bioactivity entirely to a major compound ignores whole-plant chemistry and synergy. Plant biochemistry is complex and unique with minor compounds modulating or altering the effects of the main actives. One such example is myrcene—commonly found in hops, hemp, and lemongrass essential oils, which lacks antibacterial activity in isolation but enhances the antibacterial activity of other constituents like geranial and neral against Gram-positive and Gram-negative organisms [102]. Linalool is well-known for its effects on mood state, but even essential oils rich in this constituent, like rosewood, rely upon the synergy of minor constituents to produce antidepressant activity [103]. Terpinen-4-ol, the major constituent of genuine tea tree essential oil, possesses notable antimicrobial activity, [104107] yet its anti-infectious (HSV-1) activity is a result of complex interactions among multiple constituents [108]. Similarly, the anticancer activity of mastic essential oil is attributed to the phytocomplexes of the whole essential oil rather than single constituents [109]. While instances of a single compound outperforming the whole essential oil exist, [110, 111] the buffering effects that may reduce toxicity or irritant capabilities of major active constituents cannot be ignored. Estragole—present in basil (Ocimum basilicum), fennel, and other essential oils—is considered carcinogenic but it may be inactivated by other molecules in the whole plant matrix [112]. Complex plant matrix effects require further study to confirm inactivation of toxicity or harm, from minor or major constituents, but ECS modulation by essential oils with no currently known cannabinoid suggests further research with whole essential oils is warranted.

The aforementioned studies suggest that essential oils modulate the ECS function in diverse ways both directly and indirectly. Direct binding to CB2R provides the means to modulate immune function and the inflammatory cascade. Direct agonists of CB2R allow for regulation of immune cells expressing CB2R (B cells, basophils, dendritic cells, eosinophils, mast cells, macrophages, NK cells, neutrophils, T cells, etc.) [9] and are prime targets for the treatment of various inflammatory conditions. CB2R play a critical role in alleviating perturbations involved in the pathogenesis of inflammatory conditions, ischemia/reperfusion injury, cancer, and neurodegenerative diseases [113, 114]. CB2R may work independently or cooperatively with CB1R in different cellular populations to regulate diverse biological and physiological functions in mental and physiological disorders. CB2R-selective agonists that do not generate undesirable psychoactive effects, like BCP, are increasingly appreciated from a therapeutic perspective. Myriad essential oils contain the direct selective agonist BCP, but copaiba is the leading essential oil for therapeutic use due to its significant levels.

Essential oils that modulate ECS activity represent novel therapeutics that could exert neuroprotective effects and slow disease progression in neurodegenerative disorders and conditions involving neuroinflammation, such as Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). Modified expression of CB1R and CB2R has been observed in a human brain with Alzheimer’s disease [115117]. Moreover, enhanced MAGL enzymatic activity and increased FAAH expression and activity have been observed postmortem in human Alzheimer’s disease brain [118, 119]. These findings are suggestive that pathological changes in the ECS induced by inflammation may play a role in Alzheimer’s disease. Activation of CB2R and neuroprotection by beta-caryophyllene combined with the reduction of FAAH and MAGL activity by lavender essential oil support a hypothesis that using these oils therapeutically may modulate the brain’s innate response and reduce Alzheimer’s disease progression.

Multiple sclerosis is an inflammatory demyelinating condition of the central nervous system, caused by autoimmune attack on myelin. Investigation of CBR in brain tissue samples from multiple sclerosis patients showed that CB1R- and CB2R-expressing cells are collected in active multiple sclerosis plaques and FAAH enzyme activity is induced [120]. AEA levels were strongly correlated with lesions visible on imaging. Other research suggests that endogenous endocannabinoid levels are disrupted in people with both active and silent multiple sclerosis lesions [121124]. The totality of the research suggests that dysregulation of the ECS plays a role in the pathogenesis and progression of multiple sclerosis. The use of cannabimimetic essential oils to activate CB2R, particularly beta-caryophyllene, may help regulate myelination and promote immune balance, therefore slowing multiple sclerosis progression [27]. Direct binding to CB2R by copaiba and chir pine essential oils may help normalize endocannabinoid levels and reduce inflammatory and excitotoxic assault to myelin.

ALS causes degeneration of motor neurons in the cortex, brainstem, and spinal cord, resulting in progressive loss of voluntary muscle control. The pathology of ALS is associated with neuroinflammation, mostly triggered by excitotoxicity and oxidative assault [125127]. Significantly increased CB2R-positive microglia and macrophages are noted in areas of motor neuron damage in ALS patients [128]. Dysregulation of the ECS seems to play a role in the pathogenesis of ALS, and reversing this dysregulation via CB2R could alter ALS progression. Here again, copaiba and chir pine, which act as direct CB2R agonists, are leading natural phytocompounds to investigate in ALS models.

Compounds that activate CB2R, expressed predominantly in immune cells, have neuroprotective and immunomodulatory activity that could improve the symptoms of several neuroinflammatory and neurodegenerative conditions. However, this requires further human studies to assess the effects of cannabimimetic essential oils and their effects on target receptors.

Indirect activity within the ECS—inhibition of FAAH and MAGL and activation of ECS in the CNS—represents another mechanism by which essential oils exert impactful positive modifications of the ECS and regulate human health. More research is necessary to determine which targets, mechanisms, or pathways within the ECS essential oils may regulate, in addition to direct binding to CB2R.

Multiple essential oils could be combined as a blend to modulate ECS activity, both directly and indirectly, to promote homeostasis and mitigate conditions whose pathogenesis involves dysregulation of the ECS due to the important regulatory functions of the ECS [129131]. For example, copaiba is used for a direct CB2R agonist with lavender to inhibit FAAH. Furthermore, essential oils affect the biochemistry of our cells and have various biological properties (anti-inflammatory, antinociceptive, neuroprotective, anticancer, etc.) outside the ECS, which may create a synergistic or more complete resolution of root health problems. Studies have and continue to elucidate their mechanisms of action and pharmacological targets. The wide variety of compounds and distinctive mixtures of volatile compounds in essential oils means a great diversity in the mechanism of action, molecular targets, and epigenetic influence. Efforts need to be directed towards essential oil research in relation to the ECS and other pathways and mechanisms by which they improve physiology and biochemistry.

Based on effects from both inhalation and oral administration of essential oils, it is possible that essential oils activate specific areas of the brain or influence ECS regulation via olfactory receptors [132]. This is fascinating, considering olfactory receptors are expressed outside the nasal cavity and in vital organs like the heart, liver, lungs, kidneys, and gastrointestinal tract [133, 134].

Special consideration should be given to essential oils containing high concentrations of BCP such as copaiba, hemp, and melissa. Previous research has shown their substantial therapeutic value, making it clear that BCP-containing essential oils should be among the first phytomedicines investigated in relation to the ECS and human health and disease. In particular, BCP has exhibited influence on multiple pathways involved in cancer pathogenesis and chemoprotective properties. Given the growing threat cancer poses, research with BCP and cancer should be accelerated.

5. Limitations

This review has limitations. PubMed was the only database searched for relevant publications to be included in this review. Searches with other databases may have yielded additional results. The findings of this review are limited in that only experimental data are currently available regarding how EOs modulate the ECS activity. Human clinical trials are greatly needed to confirm experimental findings and advance the use of EOs for a variety of conditions involving dysregulation of the ECS.

6. Conclusion

Emerging evidence clearly suggests that essential oils may play a role in the regulation of the ECS, its enzymatic activity, and the production of endocannabinoids and therefore represent promising phytomedicines for the treatment of diseases and conditions involving dysregulation of the ECS. Further scientific study of additional essential oils’ influence on the ECS, with an emphasis on those containing BCP, may reveal specific mechanisms of action by which essential oils modulate ECS regulatory activity. Once mechanisms are determined, human clinical trials must be conducted to determine appropriate usage and dosing in relation to the various human conditions and diseases that essential oils may benefit.


AKT:Protein kinase B
ALS:Amyotrophic lateral sclerosis
CB1R:Cannabinoid receptor type 1
CB2R:Cannabinoid receptor type 2
CBR:Cannabinoid receptor
CNS:Central nervous system
ECS:Endocannabinoid system
COX-2:Cyclooxygenase-2 (COX-2)
DHA:Docosahexaenoic acid
EPA:Eicosapentaenoic acid
FAAH:Fatty acid amide hydrolase
iNOS:Inducible nitric oxide synthase
MAGL:Monoacylglycerol lipase
MAPK:Mitogen-activated protein kinase
mTOR:Mammalian target of rapamycin
PI3K:Phosphoinositide 3-kinases
S6K1:Ribosomal protein S6 kinase beta-1
STAT3:Signal transducer and activator of transcription 3


Scott Johnson, Damian Rodriguez, and Kathryn Allred are employees of dōTERRA International (Pleasant Grove, UT, USA), a company that sells essential oils.

Conflicts of Interest

The authors declare no conflicts of interest.


This work was funded by the dōTERRA International (Pleasant Grove, UT, USA).


  1. M. E. Bergman, B. Davis, and M. A. Phillips, “Medically useful plant terpenoids: biosynthesis, occurrence, and mechanism of action,” Molecules, vol. 24, no. 21, p. 3961, 2019. View at: Publisher Site | Google Scholar
  2. S. A. Johnson, Medicinal Essential Oils: The Science and Practice of Evidence-Based Essential Oil Therapy, Scott A., Johnson Professional Writing Services LLC, Orem, UH, USA, 2017.
  3. B. Ali, N. A. Al-Wabel, S. Shams, A. Ahmad, S. A. Khan, and F. Anwar, “Essential oils used in aromatherapy: a systemic review,” Asian Pacific Journal of Tropical Biomedicine, vol. 5, no. 8, pp. 601–611, 2015. View at: Publisher Site | Google Scholar
  4. B. S. Basavarajappa, M. Shivakumar, V. Joshi, and S. Subbanna, “Endocannabinoid system in neurodegenerative disorders,” Journal of Neurochemistry, vol. 142, no. 5, pp. 624–648, 2017. View at: Publisher Site | Google Scholar
  5. R. Ranieri, C. Laezza, M. Bifulco et al., “Endocannabinoid system in neurological disorders,” Recent Patents CNS Drug Discovery, vol. 10, no. 2, pp. 90–112, 2016. View at: Publisher Site | Google Scholar
  6. T. Rubino, E. Zamberletti, and D. Parolaro, “Endocannabinoids and mental disorders,” Handbook of Experimental Pharmacology, vol. 231, pp. 261–283, 2015. View at: Publisher Site | Google Scholar
  7. F. A. Moreira, M. Grieb, and B. Lutz, “Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 23, no. 1, pp. 133–144, 2009. View at: Publisher Site | Google Scholar
  8. A. Dhopeshwarkar and K. Mackie, “CB2 cannabinoid receptors as a therapeutic target-what does the future hold?” Molecular Pharmacology, vol. 86, no. 4, pp. 430–437, 2014. View at: Publisher Site | Google Scholar
  9. C. Turcotte, M.-R. Blanchet, M. Laviolette, and N. Flamand, “The CB2 receptor and its role as a regulator of inflammation,” Cellular and Molecular Life Sciences, vol. 73, no. 23, pp. 4449–4470, 2016. View at: Publisher Site | Google Scholar
  10. J. L. Flamand and T. Yamamura, “Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?” Journal of Neuroimmunology, vol. 166, no. 2, pp. 3–18, 2005. View at: Publisher Site | Google Scholar
  11. T. W. Klein, C. A. Newton, and H. Friedman, “Cannabinoids and the immune system,” Pain Research and Management, vol. 6, no. 2, pp. 95–101, 2001. View at: Publisher Site | Google Scholar
  12. C. Turcotte, F. Chouinard, J. S. Lefebvre, and N. Flamand, “Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites,” Journal of Leukocyte Biology, vol. 97, no. 6, pp. 1049–1070, 2015. View at: Publisher Site | Google Scholar
  13. V. R. Askari and R. Shafiee-Nick, “The protective effects of β-caryophyllene on LPS-induced primary microglia M1/M2 imbalance: a mechanistic evaluation,” Life Sciences, vol. 219, no. 15, pp. 40–73, 2019. View at: Publisher Site | Google Scholar
  14. H. L. Mesquita, L. B. A. Fontes, L. A. Cinsa et al., “β-caryophyllene causes remyelination and modifies cytokines expression in C57BL/6 mice with experimental autoimmune encephalomyelitis,” Journal of Applied Pharmaceutical Sciences, vol. 9, no. 7, pp. 27–33, 2019. View at: Publisher Site | Google Scholar
  15. W.-S. Lee, K. Erdelyi, C. Matyas et al., “Cannabidiol limits T cell-mediated chronic autoimmune Myocarditis: implications to autoimmune disorders and organ transplantation,” Molecular Medicine, vol. 22, no. 1, pp. 136–146, 2016. View at: Publisher Site | Google Scholar
  16. A. Zgair, J. B. Lee, J. C. M. Wong et al., “Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation,” Scientific Reports, vol. 7, no. 1, p. 14542, 2017. View at: Publisher Site | Google Scholar
  17. L. K. Miller and L. A. Devi, “The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications,” Pharmacological Reviews, vol. 63, no. 3, pp. 461–470, 2011. View at: Publisher Site | Google Scholar
  18. P. Pacher, S. Bátkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006. View at: Publisher Site | Google Scholar
  19. C. A. Sallaberry and L. Astern, “The endocannabinoid system, our universal regulator,” Journal of Young Investigators, vol. 34, no. 6, pp. 48–55, 2018. View at: Publisher Site | Google Scholar
  20. R. D. Trindade, J. K. da Silva, and W. N. Setzer, “Copaifera of the Neotropics: a review of the phytochemistry and pharmacology,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1511, 2018. View at: Publisher Site | Google Scholar
  21. A. N. Menon, K. P. Padmakumari, and A. Jayalekshmy, “Essential oil composition of four major cultivars of black pepper (Piper nigrum L.) III,” Journal of Essential Oil Research, vol. 15, no. 3, pp. 155–157, 2003. View at: Publisher Site | Google Scholar
  22. H. Moradkhani, E. Sargsyan, H. Bibak et al., “Melissa officinalis L., a valuable medicine plant: a review,” Journal of Medicinal Plant Research, vol. 4, no. 25, pp. 2753–2759, 2010. View at: Google Scholar
  23. A. Arain, S. T. H. Sherazi, S. Mahesar et al., “Essential oil from Psidium guajava leaves: an excellent source of β-caryophyllene,” Natural Product Communications, vol. 14, no. 5, Article ID 1934578X1984300, 2019. View at: Publisher Site | Google Scholar
  24. A. Bertoli, S. Tozzi, L. Pistelli, and L. G. Angelini, “Fibre hemp inflorescences: from crop-residues to essential oil production,” Industrial Crops and Products, vol. 32, no. 3, pp. 329–337, 2010. View at: Publisher Site | Google Scholar
  25. L. T. H. Angelini, L. H. Lee, W. F. Yin et al., “Traditional uses, phytochemistry, and bioactivities of Cananga odorata (Ylang-Ylang),” Evidence Based Complementary and Alternative Medicine, vol. 2015, Article ID 896314, 30 pages, 2015. View at: Publisher Site | Google Scholar
  26. J. Gertsch, M. Leonti, S. Raduner et al., “Beta-caryophyllene is a dietary cannabinoid,” Proceedings of the National Academy of Sciences, vol. 105, no. 26, pp. 9099–9104, 2008. View at: Publisher Site | Google Scholar
  27. T. Alberti, W. Barbosa, J. Vieira, N. Raposo, and D. Rafael, “(−)-β-caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a Murine model of multiple sclerosis,” International Journal of Molecular Sciences, vol. 18, no. 4, p. 691, 2017. View at: Publisher Site | Google Scholar
  28. J. Gertsch, “Antiinflammatory cannabinoids in diet-towards a better understanding of CB2 receptor action?” Communicative & Integrative Biology, vol. 1, no. 1, pp. 26–28, 2008. View at: Publisher Site | Google Scholar
  29. C. Sharma, J. M. Al Kaabi, S. M. Nurulain, S. N. Goyal, M. A. Kamal, and S. Ojha, “Polypharmacological properties and therapeutic potential of β-caryophyllene: a dietary phytocannabinoid of pharmaceutical promise,” Current Pharmaceutical Design, vol. 22, no. 21, pp. 3237–3264, 2016. View at: Publisher Site | Google Scholar
  30. A.-L. Klauke, I. Racz, B. Pradier et al., “The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain,” European Neuropsychopharmacology, vol. 24, no. 4, pp. 608–620, 2014. View at: Publisher Site | Google Scholar
  31. L. Paula‐Freire, M. Andersen, V. Gama et al., “The oral administration of trans‐caryophyllene attenuates acute and chronic pain in mice,” Phytomedicine, vol. 21, no. 3, pp. 356–362, 2014. View at: Publisher Site | Google Scholar
  32. S. A. Johnson, Supercritical Essential Oils. A Companion Resource to Medicinal Essential Oils, Scott A Johnson Professional Writing Services, LLC, Orem, UH, USA, 2017.
  33. S. Katsuyama, H. Mizoguchi, H. Kuwahata et al., “Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception,” European Journal of Pain, vol. 17, no. 5, pp. 664–675, 2013. View at: Publisher Site | Google Scholar
  34. K. Fidyt, A. Fiedorowicz, L. Strządała, and A. Szumny, “β‐caryophyllene and β‐caryophyllene oxide-natural compounds of anticancer and analgesic properties,” Cancer Medicine, vol. 5, no. 10, pp. 3007–3017, 2016. View at: Publisher Site | Google Scholar
  35. C. Szumny, S. K. Cho, K.-D. Kim et al., “β-caryophyllene oxide potentiates TNFα-induced apoptosis and inhibits invasion through down-modulation of NF-κB-regulated gene products,” Apoptosis, vol. 19, no. 4, pp. 708–718, 2014. View at: Publisher Site | Google Scholar
  36. A. Di Sotto, G. Mazzanti, F. Carbone et al., “Inhibition by beta-caryophyllene of ethyl methanesulfonate-induced clastogenicity in cultured human lymphocytes,” Mutation Research, vol. 699, no. 2, pp. 23–28, 2010. View at: Publisher Site | Google Scholar
  37. G.-Q. Zheng, P. M. Kenney, and L. K. T. Lam, “Sesquiterpenes from clove (Eugenia caryophyllata) as potential anticarcinogenic agents,” Journal of Natural Products, vol. 55, no. 7, pp. 999–1003, 1992. View at: Publisher Site | Google Scholar
  38. S. Di Giacomo, G. Mazzanti, and A. Di Sotto, “Mutagenicity of cigarette butt waste in the bacterial reverse mutation assay: the protective effects of β-caryophyllene and β-caryophyllene oxide,” Environmental Toxicology, vol. 31, no. 11, pp. 1319–1328, 2016. View at: Publisher Site | Google Scholar
  39. A. Di Sotto, M. G. Evandri, and G. Mazzanti, “Antimutagenic and mutagenic activities of some terpenes in the bacterial reverse mutation assay,” Mutation Research, vol. 653, no. 2, pp. 130–133, 2008. View at: Publisher Site | Google Scholar
  40. E. S. Hwang, H. B. Kim, S. Lee et al., “Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression,” Behavioural Brain Research, vol. 380, Article ID 112439, 2020. View at: Publisher Site | Google Scholar
  41. K. D. C. Machado, M. T. Islam, E. S. Ali et al., “A systematic review on the neuroprotective perspectives of beta-caryophyllene,” Phytotherapy Research, vol. 32, no. 12, pp. 2376–2388, 2018. View at: Publisher Site | Google Scholar
  42. M. D. Baldissera, C. F. Souza, T. H. Grando et al., “Hypolipidemic effect of β-caryophyllene to treat hyperlipidemic rats,” Naunyn Schmiedebergs Archives of Pharmacology, vol. 390, no. 2, pp. 215–223, 2016. View at: Publisher Site | Google Scholar
  43. J. Tchekalarova, K. da Conceição Machado, A. L. Gomes Júnior, A. de Carvalho Melo Cavalcante, A. Momchilova, and R. Tzoneva, “Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice,” Seizure, vol. 57, pp. 22–26, 2018. View at: Publisher Site | Google Scholar
  44. M. A. Abbas, M. O. Taha, M. A. Zihlif et al., “β-caryophyllene causes regression of endometrial implants in a rat model of endometriosis without affecting fertility,” European Journal of Pharmacology, vol. 702, no. 1–3, pp. 12–19, 2013. View at: Publisher Site | Google Scholar
  45. R. H. Basha and C. Sankaranarayanan, “β-caryophyllene, a natural sesquiterpene, modulates carbohydrate metabolism in streptozotocin-induced diabetic rats,” Acta Histochemica, vol. 116, no. 8, pp. 1469–1479, 2014. View at: Publisher Site | Google Scholar
  46. R. H. Basha and C. Sankaranarayanan, “β-caryophyllene, a natural sesquiterpene lactone attenuates hyperglycemia mediated oxidative and inflammatory stress in experimental diabetic rats,” Chemico-Biological Interactions, vol. 245, pp. 50–58, 2016. View at: Publisher Site | Google Scholar
  47. H.-I. Cho, J.-M. Hong, J.-W. Choi et al., “β-caryophyllene alleviates d-galactosamine and lipopolysaccharide-induced hepatic injury through suppression of the TLR4 and RAGE signaling pathways,” European Journal of Pharmacology, vol. 764, pp. 613–621, 2015. View at: Publisher Site | Google Scholar
  48. M. F. Mahmoud, S. E. Swefy, R. A. Hasan, and A. Ibrahim, “Role of cannabinoid receptors in hepatic fibrosis and apoptosis associated with bile duct ligation in rats,” European Journal of Pharmacology, vol. 742, pp. 118–124, 2014. View at: Publisher Site | Google Scholar
  49. M. A. Ibrahim, J. M. Vieites, T. Montero-Meterdez et al., “The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation,” British Journal of Nutrition, vol. 109, no. 3, pp. 394–401, 2013. View at: Publisher Site | Google Scholar
  50. M. E. Kelany and M. A. Abdallah, “Protective effects of combined β-caryophyllene and silymarin against ketoprofen-induced hepatotoxicity in rats,” Canadian Journal of Physiology and Pharmacology, vol. 94, no. 7, pp. 739–744, 2016. View at: Publisher Site | Google Scholar
  51. R. Kamikubo, K. Kai, K. Tsuji-Naito, and M. Akagawa, “β-caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes,” Molecular Nutrition & Food Research, vol. 60, no. 10, pp. 2228–2242, 2016. View at: Publisher Site | Google Scholar
  52. G. Akagawa, N. Arora, I. Burkovskiy et al., “Experimental cannabinoid 2 receptor activation by phyto-derived and synthetic cannabinoid ligands in lps-induced interstitial cystitis in mice,” Molecules, vol. 24, no. 23, Article ID 24234239, 2019. View at: Publisher Site | Google Scholar
  53. E. Galaj and Z.-X. Xi, “Potential of cannabinoid receptor ligands as treatment for substance use disorders,” CNS Drugs, vol. 33, no. 10, pp. 1001–1030, 2019. View at: Publisher Site | Google Scholar
  54. S. Robu, A. C. Aprotosoaie, A. Spac et al., “Studies regarding chemical composition of lavender volatile oils,” Revista Medico-Chirurgicala a Societatii de Medicii si Naturalisti din Iasi, vol. 115, no. 2, pp. 584–589, 2011. View at: Google Scholar
  55. O. Doroshyenko, D. Rokitta, G. Zadoyan et al., “Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers,” Drug Metabolism and Disposition, vol. 41, no. 5, pp. 987–993, 2013. View at: Publisher Site | Google Scholar
  56. D. J. Beale, P. D. Morrison, A. V. Karpe, and M. S. Dunn, “Chemometric analysis of lavender essential oils using targeted and untargeted GC-MS acquired data for the rapid identification and characterization of oil quality,” Molecules, vol. 22, no. 8, p. 1339, 2017. View at: Publisher Site | Google Scholar
  57. P. H. Dunn, M. K. Ghadiri, and A. Gorji, “Lavender and the nervous system,” Evidence Based Complementary and Alternative Medicine, vol. 2013, Article ID 681304, 10 pages, 2013. View at: Publisher Site | Google Scholar
  58. M. D. Sanna, F. Les, V. Lopez et al., “Lavender (Lavandula angustifolia Mill.) essential oil alleviates neuropathic pain in mice with spared nerve injury,” Frontiers in Pharmacology, vol. 10, p. 472, 2019. View at: Publisher Site | Google Scholar
  59. K. Ahn, D. S. Johnson, and B. F. Cravatt, “Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders,” Expert Opinion on Drug Discovery, vol. 4, no. 7, pp. 763–784, 2009. View at: Publisher Site | Google Scholar
  60. G. Griebel, J. Stemmelin, M. Lopez-Grancha et al., “The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents,” Scientific Reports, vol. 8, no. 1, p. 2416, 2018. View at: Publisher Site | Google Scholar
  61. J. D. Richardson, L. Aanonsen, and K. M. Hargreaves, “Antihyperalgesic effects of spinal cannabinoids,” European Journal of Pharmacology, vol. 345, no. 2, pp. 145–153, 1998. View at: Publisher Site | Google Scholar
  62. Z. Helyes, J. Németh, M. Thán, K. Bölcskei, E. Pintér, and J. Szolcsányi, “Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat,” Life Sciences, vol. 73, no. 18, pp. 2345–2353, 2003. View at: Publisher Site | Google Scholar
  63. N. S. Canteras, L. B. Resstel, L. J. Bertoglio, P. CarobrezAde, and F. S. Guimarães, “Neuroanatomy of anxiety,” Current Topics in Behavioral Neurosciences, vol. 2, no. 2, pp. 77–96, 2010. View at: Publisher Site | Google Scholar
  64. E. M. Marco, C. Rapino, A. Caprioli et al., “Potential therapeutic value of a novel FAAH inhibitor for the treatment of anxiety,” PLoS One, vol. 10, no. 9, Article ID e0137034, 2015. View at: Publisher Site | Google Scholar
  65. S. Petrosino and V. Di Marzo, “FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels,” Current Opinion in Investigational Drugs, vol. 11, no. 1, pp. 51–62, 2010. View at: Google Scholar
  66. L. Brunetti, A. Laghezza, F. Loiodice et al., “Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease,” Neural Regeneration Research, vol. 15, no. 1, pp. 67-68, 2020. View at: Publisher Site | Google Scholar
  67. A. M. Saab, I. Lampronti, M. Borgatti et al., “In vitro evaluation of the anti-proliferative activities of the wood essential oils of three Cedrus species against K562 human chronic myelogenous leukaemia cells,” Natural Product Research, vol. 26, no. 23, pp. 2227–2231, 2012. View at: Publisher Site | Google Scholar
  68. S. Baylac and P. Racine, “Inhibition of 5-lipoxygenase by essential oils and other natural fragrant extracts,” International Journal of Aromatherapy, vol. 13, no. 2-3, pp. 138–142, 2003. View at: Publisher Site | Google Scholar
  69. D. F. Martins, A. A. Emer, A. P. Batisti et al., “Inhalation of Cedrus atlantica essential oil alleviates pain behavior through activation of descending pain modulation pathways in a mouse model of postoperative pain,” Journal of Ethnopharmacology, vol. 175, pp. 30–38, 2015. View at: Publisher Site | Google Scholar
  70. R. Pazinato, A. Volpato, M. D. Baldissera et al., “In vitro effect of seven essential oils on the reproduction of the cattle tick Rhipicephalus microplus,” Journal of Advanced Research, vol. 7, no. 6, pp. 1029–1034, 2016. View at: Publisher Site | Google Scholar
  71. A. A. Emer, N. N. Donatello, A. P. Batisti, L. A. Oliveira Belmonte, R. S. Adair, and D. F. Martins, “The role of the endocannabinoid system in the antihyperalgesic effect of Cedrus atlantica essential oil inhalation in a mouse model of postoperative pain,” Journal of Ethnopharmacology, vol. 210, pp. 477–484, 2018. View at: Publisher Site | Google Scholar
  72. A. Maxia, C. Sanna, M. A. Frau et al., “Anti-inflammatory activity of Pistacia lentiscus essential oil: involvement of IL-6 and TNF-alpha,” Natural Product Communications, vol. 6, no. 10, pp. 1543-1544, 2011. View at: Publisher Site | Google Scholar
  73. H. Ahmamdi, F. Aouinti, J. P. Wathelet et al., “Chemical composition of the essential oil of Pistacia lentiscus L. from Eastern Morocco,” Records of Natural Products, vol. 3, no. 2, pp. 90–95, 2009. View at: Google Scholar
  74. O. Bachrouch, J. M. B. Jemaa, T. Talou et al., “Fumigant toxicity of Pistacia lentiscus essential oil against Tribolium castaneum and Lasioderma serricorne,” Bulletin of Insectology, vol. 63, no. 1, pp. 129–135, 2010. View at: Google Scholar
  75. M. Quartu, M. Serra, M. Boi et al., “Effect of acute administration of Pistacia lentiscus L. essential oil on rat cerebral cortex following transient bilateral common carotid artery occlusion,” Lipids in Health and Disease, vol. 11, no. 1, p. 8, 2012. View at: Publisher Site | Google Scholar
  76. U. Dirnagl, C. Iadecola, and M. A. Moskowitz, “Pathobiology of ischaemic stroke: an integrated view,” Trends in Neurosciences, vol. 22, no. 9, pp. 391–397, 1999. View at: Publisher Site | Google Scholar
  77. B. C. White, J. M. Sullivan, D. J. DeGracia et al., “Brain ischemia and reperfusion: molecular mechanisms of neuronal injury,” Journal of the Neurological Sciences, vol. 179, no. 1-2, pp. 1–33, 2000. View at: Publisher Site | Google Scholar
  78. H. Shi and K. J. Liu, “Cerebral tissue oxygenation and oxidative brain injury during ischemia and reperfusion,” Frontiers in Bioscience, vol. 12, no. 1, pp. 1318–1328, 2007. View at: Publisher Site | Google Scholar
  79. B. Kold, H. Saber, H. Fadel et al., “The endocannabinoid system and stroke: a focused review,” Brain Circulation, vol. 5, no. 1, pp. 1–7, 2019. View at: Publisher Site | Google Scholar
  80. C. Hillard, “Role of cannabinoids and endocannabinoids in cerebral ischemia,” Current Pharmaceutical Design, vol. 14, no. 23, pp. 2347–2361, 2008. View at: Publisher Site | Google Scholar
  81. M. T. Viscomi, S. Oddi, L. Latini et al., “Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway,” Journal of Neuroscience, vol. 29, no. 14, pp. 4564–4570, 2009. View at: Publisher Site | Google Scholar
  82. M. D. Van Sickle, M. Duncan, P. J. Kingsley et al., “Identification and functional characterization of brainstem cannabinoid CB2 receptors,” Science, vol. 310, no. 5746, pp. 329–332, 2002. View at: Publisher Site | Google Scholar
  83. G. A. Cabral and L. Griffin-Thomas, “Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation,” Expert Reviews in Molecular Medicine, vol. 11, no. 1, p. e3, 2009. View at: Publisher Site | Google Scholar
  84. L. S. A. Capettini, S. Q. Savergnini, R. F. da Silva et al., “Update on the role of cannabinoid receptors after ischemic stroke,” Mediators of Inflammation, vol. 2012, Article ID 824093, 8 pages, 2012. View at: Publisher Site | Google Scholar
  85. J. Fernández-Ruiz, M. A. Moro, and J. Martínez-Orgado, “Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications,” Neurotherapeutics, vol. 12, no. 4, pp. 793–806, 2015. View at: Publisher Site | Google Scholar
  86. L. Poddighe, G. Carta, M. P. Serra et al., “Acute administration of beta-caryophyllene prevents endocannabinoid system activation during transient common carotid artery occlusion and reperfusion,” Lipids in Health and Disease, vol. 17, no. 1, p. 23, 2018. View at: Publisher Site | Google Scholar
  87. R. Labib, F. Youssef, M. Ashour, M. Abdel-Daim, and S. Ross, “Chemical composition of pinus roxburghii bark volatile oil and validation of its anti-inflammatory activity using molecular modelling and bleomycin-induced inflammation in albino mice,” Molecules, vol. 22, no. 9, p. 1384, 2017. View at: Publisher Site | Google Scholar
  88. S. Chung, G. H. Son, and K. Kim, “Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1812, no. 5, pp. 581–591, 2011. View at: Publisher Site | Google Scholar
  89. M. N. Hill, R. J. McLaughlin, A. C. Morrish et al., “Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis,” Neuropsychopharmacology, vol. 34, no. 13, pp. 2733–2745, 2009. View at: Publisher Site | Google Scholar
  90. M. N. Hill, I. N. Karatsoreos, C. J. Hillard, and B. S. Mcewen, “Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo,” Psychoneuroendocrinology, vol. 35, no. 9, pp. 1333–1338, 2010. View at: Publisher Site | Google Scholar
  91. C. McEwen and H. S. Hundal, “Modulation of cellular redox homeostasis by the endocannabinoid system,” Open Biology, vol. 6, no. 4, Article ID 150276, 2016. View at: Publisher Site | Google Scholar
  92. Y. Asakawa, T. Ishida, M. Toyota, and T. Takemoto, “Terpenoid biotransformation in mammals IV Biotransformation of (+)-longifolene, (-)-caryophyllene, (-)-caryophyllene oxide, (-)-cyclocolorenone, (+)-nootkatone, (-)-elemol, (-)-abietic acid and (+)-dehydroabietic acid in rabbits,” Xenobiotica, vol. 16, no. 8, pp. 753–767, 1986. View at: Publisher Site | Google Scholar
  93. N. Takemoto, O. Bachrouch, S. Bousselmi et al., “Chemical composition and antioxidant and antimicrobial activities of wormwood (Artemisia absinthium L.) essential oils and phenolics,” Journal of Chemistry, vol. 2015, Article ID 804658, 12 pages, 2015. View at: Publisher Site | Google Scholar
  94. A. Mohammadi, T. A. Sani, A. A. Ameri et al., “Seasonal variation in the chemical composition, antioxidant activity, and total phenolic content of Artemisia absinthium essential oils,” Pharmacognosy Research, vol. 7, no. 4, pp. 329–334, 2015. View at: Publisher Site | Google Scholar
  95. M. Bailen, L. F. Julio, C. E. Diaz et al., “Chemical composition and biological effects of essential oils from Artemisia absinthium L. cultivated under different environmental conditions,” Industrial Crops and Products, vol. 49, pp. 102–107, 2013. View at: Publisher Site | Google Scholar
  96. D. D. Vogt, “Absinthium: a nineteenth-century drug of abuse,” Journal of Ethnopharmacology, vol. 4, no. 3, pp. 337–342, 1981. View at: Publisher Site | Google Scholar
  97. J. Strang, W. N. Arnold, and T. Peters, “Absinthe: what’s your poison?” BMJ, vol. 319, no. 7225, pp. 1590–1592, 1999. View at: Publisher Site | Google Scholar
  98. N. Radulovic, M. S. Gencic, N. M. Stojanovic et al., “Toxic essential oils. Part V: behaviour modulating and toxic properties of thujones and thujone-containing essential oils of Salvia officinalis L., Artemisia absinthium L., Thuja occidentalis L. and Tanacetum vulgare L,” Food and Chemical Toxicology, vol. 105, pp. 355–369, 2017. View at: Publisher Site | Google Scholar
  99. J. Meschler and A. C. Howlett, “Thujone exhibits low affinity for Cannabinoid receptors but fails to evoke cannabimimetic responses,” Pharmacology Biochemistry and Behavior, vol. 62, no. 3, pp. 473–480, 1999. View at: Publisher Site | Google Scholar
  100. J. Gertsch, “Cannabimimetic phytochemicals in the diet-an evolutionary link to food selection and metabolic stress adaptation?” British Journal of Pharmacology, vol. 174, no. 11, pp. 1464–1483, 2017. View at: Publisher Site | Google Scholar
  101. D. R. Janero and A. Makriyannis, “Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems,” ACS Chemical Neuroscience, vol. 5, no. 11, pp. 1097–1106, 2014. View at: Publisher Site | Google Scholar
  102. G. O. Onawunmi, W.-A. Yisak, and E. O. Ogunlana, “Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.) Stapf,” Journal of Ethnopharmacology, vol. 12, no. 3, pp. 279–286, 1984. View at: Publisher Site | Google Scholar
  103. É. R. Q. dos Santos, C. S. F. Maia, E. A. Fontes Junior, A. S. Melo, B. G. Pinheiro, and J. G. S. Maia, “Linalool-rich essential oils from the Amazon display antidepressant-type effect in rodents,” Journal of Ethnopharmacology, vol. 212, pp. 43–49, 2018. View at: Publisher Site | Google Scholar
  104. C. Kurekci, J. Padmanabha, S. L. Bishop-Hurley, E. Hassan, R. A. M. Al Jassim, and C. S. McSweeney, “Antimicrobial activity of essential oils and five terpenoid compounds against Campylobacter jejuni in pure and mixed culture experiments,” International Journal of Food Microbiology, vol. 166, no. 3, pp. 450–457, 2013. View at: Publisher Site | Google Scholar
  105. K. A. Hammer, C. F. Carson, and T. V. Riley, “Effects of Melaleuca alternifolia (tea tree) essential oil and the major monoterpene component terpinen-4-ol on the development of single- and multistep antibiotic resistance and antimicrobial susceptibility,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 2, pp. 909–915, 2012. View at: Publisher Site | Google Scholar
  106. C.-J. Lee, L.-W. Chen, L.-G. Chen et al., “Correlations of the components of tea tree oil with its antibacterial effects and skin irritation,” Journal of Food and Drug Analysis, vol. 21, no. 2, pp. 169–176, 2013. View at: Publisher Site | Google Scholar
  107. P. M. Maquera Huacho, E. Rodriguez Herrero, T. Verspecht et al., “Terpinen-4-ol and carvacrol affect multi-species biofilm composition,” Biofouling, vol. 35, no. 5, pp. 561–572, 2019. View at: Publisher Site | Google Scholar
  108. P. Brun, G. Bernabè, R. Filippini et al., “In Vitro antimicrobial activities of commercially available tea tree (Melaleuca alternifolia) essential oils,” Current Microbiology, vol. 76, no. 1, pp. 108–116, 2018. View at: Publisher Site | Google Scholar
  109. A. Buriani, S. Fortinguerra, V. Sorrenti et al., “Human adenocarcinoma cell line sensitivity to essential oil phytocomplexes from Pistacia species: a multivariate approach,” Molecules, vol. 22, no. 8, p. e1336, 2019. View at: Publisher Site | Google Scholar
  110. T. A. de Souza, M. B. P. Lopes, A. S. Ramos et al., “Alpinia essential oils and their major components against Rhodnius nasutus, a vector of chagas disease,” Scientific World Journal, vol. 2018, Article ID 2393858, 6 pages, 2018. View at: Publisher Site | Google Scholar
  111. E. J. Muturi, K. Doll, J. L. Ramirez, and A. P. Rooney, “Bioactivity of wild carrot (Daucus carota, Apiaceae) essential oil against mosquito larvae,” Journal of Medical Entomology, vol. 56, no. 3, pp. 784–789, 2018. View at: Publisher Site | Google Scholar
  112. L. Gori, E. Gallo, V. Mascherini et al., “Can estragole in fennel seed decoctions really be considered a danger for human health? a fennel safety update,” Evidence Based Complementary and Alternative Medicine, vol. 2012, Article ID 860542, 10 pages, 2012. View at: Publisher Site | Google Scholar
  113. K. D. Patel, J. S. Davision, Q. J. Pittman, and K. Sharkry, “Cannabinoid CB2 receptors in health and disease,” Current Medicinal Chemistry, vol. 17, no. 4, pp. 1394–1410, 2010. View at: Publisher Site | Google Scholar
  114. T. Cassano, S. Calcagnini, L. Pace et al., “Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target,” Frontiers in Neuroscience, vol. 11, p. 30, 2017. View at: Publisher Site | Google Scholar
  115. T. M. Westlake, A. C. Howlett, T. I. Bonner, L. A. Matsuda, and M. Herkenham, “Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains,” Neuroscience, vol. 63, no. 3, pp. 637–652, 1994. View at: Publisher Site | Google Scholar
  116. C. Benito, E. Núñez, R. M. Tolón et al., “Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains,” The Journal of Neuroscience, vol. 23, no. 35, pp. 11136–11141, 2003. View at: Publisher Site | Google Scholar
  117. B. G. Ramirez, C. Blázquez, T. Gómez del Pulgar et al., “Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation,” Journal of Neuroscience, vol. 25, no. 8, pp. 1904–1913, 2005. View at: Publisher Site | Google Scholar
  118. A. A. Farooqui, L. Liss, and L. A. Horrocks, “Stimulation of lipolytic enzymes in Alzheimer’s disease,” Annals of Neurology, vol. 23, no. 3, pp. 306–308, 1988. View at: Publisher Site | Google Scholar
  119. J. Koppel, H. Bradshaw, T. E. Goldberg et al., “Endocannabinoids in Alzheimer’s disease and their impact on normative cognitive performance: a case-control and cohort study,” Lipids in Health and Disease, vol. 8, no. 1, p. 2, 2009. View at: Publisher Site | Google Scholar
  120. C. Benito, J. P. Romero, R. M. Tolon et al., “Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis,” Journal of Neuroscience, vol. 27, no. 9, pp. 2396–2402, 2007. View at: Publisher Site | Google Scholar
  121. D. Centonze, M. Bari, S. Rossi et al., “The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis,” Brain, vol. 130, no. 10, pp. 2543–2553, 2007. View at: Publisher Site | Google Scholar
  122. L. Jean-Gilles, S. Feng, C. R. Tench et al., “Plasma endocannabinoid levels in multiple sclerosis,” Journal of the Neurological Sciences, vol. 287, no. 1-2, pp. 212–215, 2009. View at: Publisher Site | Google Scholar
  123. M. Di Filippo, L. A. Pini, G. P. Pelliccioli, P. Calabresi, and P. Sarchielli, “Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 79, no. 11, pp. 1224–1229, 2008. View at: Publisher Site | Google Scholar
  124. A. J. Sánchez López, L. Román-Vega, E. Ramil Tojeiro, A. Giuffrida, and M. Garcίa, “Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients,” Clinical & Experimental Immunology, vol. 179, no. 1, pp. 119–127, 2015. View at: Publisher Site | Google Scholar
  125. A. C. Ludolph, T. Meyer, and M. W. Riepe, “The role of excitotoxicity in ALS—what is the evidence?” Journal of Neurology, vol. 247, no. 1, pp. 16-17, 2000. View at: Publisher Site | Google Scholar
  126. W. Robberecht, “Oxidative stress in amyotrophic lateral sclerosis,” Journal of Neurology, vol. 247, no. 1, pp. 1–6, 2000. View at: Publisher Site | Google Scholar
  127. D. W. Cleveland and J. D. Rothstein, “From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS,” Nature Reviews Neuroscience, vol. 2, no. 11, pp. 806–819, 2001. View at: Publisher Site | Google Scholar
  128. Y. Yiangou, P. Facer, P. Durrenberger et al., “CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord,” BMC Neurology, vol. 6, p. 12, 2006. View at: Publisher Site | Google Scholar
  129. C. Sharma, B. Sadek, S. N. Goyal et al., “Small molecules from nature targeting g-protein coupled Cannabinoid receptors: potential leads for drug discovery and development,” Evidence Based Complementary and Alternative Medicine, vol. 2015, Article ID 238482, 26 pages, 2015. View at: Publisher Site | Google Scholar
  130. N. Gulluni, T. Re, I. Loiacono et al., “Cannabis essential oil: a preliminary study for the evaluation of the brain effects,” Evidence Based Complementary and Alternative Medicine, vol. 2018, Article ID 1709182, 11 pages, 2018. View at: Publisher Site | Google Scholar
  131. P. Pacher and G. Kunos, “Modulating the endocannabinoid system in human health and disease-successes and failures,” FEBS Journal, vol. 280, no. 9, pp. 1918–1943, 2013. View at: Publisher Site | Google Scholar
  132. T. Heinbockel, Z. J. Wang, E. A. Brown et al., “Endocannabinoid signaling in neural circuits of the olfactory and limbic system,” Cannabinoids in Health and Disease, IntechOpen, London, UK, 2016, https://www.intechopen.com/books/cannabinoids-in-health-and-disease/endocannabinoid-signaling-in-neural-circuits-of-the-olfactory-and-limbic-system. View at: Google Scholar
  133. B. D. Shephard and J. L. Pluznick, “How does your kidney smell? Emerging roles for olfactory receptors in renal function,” Pediartric Nephrology, vol. 31, no. 5, pp. 715–723, 2016. View at: Publisher Site | Google Scholar
  134. D. MaBerg and H. Hatt, “Human olfactory receptors: novel cellular functions outside of the nose,” Physiological Reviews, vol. 98, no. 3, pp. 1739–1763, 2018. View at: Publisher Site | Google Scholar

Copyright © 2020 Scott A. Johnson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles